Terazosin Suppresses Endometriosis Progression via Downregulation of Steroidogenic Factor-1: An Experimental Rat Model
Terazosin suppressed endometriosis progression in a rat model by downregulating steroidogenic factor-1.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
This experimental study utilized a surgically induced rat model to evaluate the therapeutic efficacy of terazosin, an alpha-1 adrenergic receptor antagonist, on endometriosis progression. The researchers analyzed raw biochemical and molecular data to determine how the treatment affected disease markers in the animal subjects. Key findings indicated that terazosin suppressed endometriosis progression by downregulating the expression of steroidogenic factor-1 within the tissue samples. This paper is centrally about endometriosis — specifically investigating a pharmacological intervention using terazosin to inhibit lesion growth via molecular pathway modulation.
Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works
Abstract
Full text
506 characters
· extracted from
oa-html
· click to expand
Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.
My notes (saved in your browser only)
Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works
Condition tags
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.
Source provenance
- openalex
- last seen: 2026-06-29T06:01:59.144155+00:00